JP2017501227A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501227A5
JP2017501227A5 JP2016560871A JP2016560871A JP2017501227A5 JP 2017501227 A5 JP2017501227 A5 JP 2017501227A5 JP 2016560871 A JP2016560871 A JP 2016560871A JP 2016560871 A JP2016560871 A JP 2016560871A JP 2017501227 A5 JP2017501227 A5 JP 2017501227A5
Authority
JP
Japan
Prior art keywords
composition
hours
acid
minutes
alginic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016560871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071664 external-priority patent/WO2015095793A1/en
Publication of JP2017501227A publication Critical patent/JP2017501227A/ja
Publication of JP2017501227A5 publication Critical patent/JP2017501227A5/ja
Pending legal-status Critical Current

Links

JP2016560871A 2013-12-19 2014-12-19 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 Pending JP2017501227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361918445P 2013-12-19 2013-12-19
US61/918,445 2013-12-19
PCT/US2014/071664 WO2015095793A1 (en) 2013-12-19 2014-12-19 Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020063444A Division JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2017501227A JP2017501227A (ja) 2017-01-12
JP2017501227A5 true JP2017501227A5 (enExample) 2017-12-07

Family

ID=53403777

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016560871A Pending JP2017501227A (ja) 2013-12-19 2014-12-19 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2020063444A Pending JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2022017393A Pending JP2022070924A (ja) 2013-12-19 2022-02-07 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020063444A Pending JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2022017393A Pending JP2022070924A (ja) 2013-12-19 2022-02-07 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Country Status (15)

Country Link
US (3) US11337989B2 (enExample)
EP (2) EP3735966A1 (enExample)
JP (3) JP2017501227A (enExample)
KR (1) KR102407408B1 (enExample)
CN (2) CN114452298A (enExample)
AU (2) AU2014368971B2 (enExample)
BR (1) BR112016014506B1 (enExample)
DK (1) DK3082826T3 (enExample)
ES (1) ES2790703T3 (enExample)
IL (1) IL246146B2 (enExample)
MX (2) MX2016008023A (enExample)
NZ (1) NZ722215A (enExample)
RU (1) RU2691950C1 (enExample)
WO (1) WO2015095793A1 (enExample)
ZA (1) ZA201604862B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487054A (zh) 2012-06-13 2015-04-01 伊沃菲姆股份有限公司 用于增强避孕杀微生物剂有效性的组合物和方法
MX2016008023A (es) 2013-12-19 2017-01-13 Evofem Inc Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.
DE102017110168A1 (de) 2016-05-25 2017-11-30 Samsung Electronics Co., Ltd. Elektronische Vorrichtung mit NFC-Antenne
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
US11419835B2 (en) 2016-10-04 2022-08-23 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
WO2023076968A1 (en) * 2021-10-28 2023-05-04 Evofem, Inc. Rapidly dissolving vaginal film with contraceptive action and sexually transmitted infection prevention

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
AU1661901A (en) 1999-11-24 2001-06-04 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
RU2274442C2 (ru) * 2000-03-07 2006-04-20 Раш-Презбитериан-Ст. Лук'С Медикал Сентер Композиции и способы улавливания и инактивации патогенных микроорганизмов и сперматозоидов
JP2009102407A (ja) * 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Gリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
JP2004537525A (ja) * 2001-06-11 2004-12-16 メルク エンド カムパニー インコーポレーテッド PPARδアゴニストの投与による炎症性疾患の治療法
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
WO2004011032A1 (ja) * 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
CN101534863A (zh) * 2006-11-10 2009-09-16 日本乐敦制药株式会社 用于向皮肤或粘膜施用的组合物
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
HRP20140559T1 (hr) 2007-03-30 2014-08-01 Laccure Ab Uporaba oligomera mlijeäśne kiseline u lijeäśenju ginekoloških infekcija
WO2008148018A2 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2282777A1 (en) 2008-04-16 2011-02-16 Cipla Limited Topical combinations comprising an antimycotic agent and an antiviral agent
WO2009155118A1 (en) * 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
WO2010142761A1 (en) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. The succinate of tenofovir disoproxil
KR20160112012A (ko) * 2011-05-02 2016-09-27 아데어 파마슈티컬스 인코포레이티드 질내 투여용 속용성 정제 조성물
JP5986632B2 (ja) 2011-06-28 2016-09-06 メディシス ファーマシューティカル コーポレイション 高用量粘膜接着性メトロニダゾール水系ゲル製剤および細菌性膣炎を治療するためのそれらの使用
CN104487054A (zh) 2012-06-13 2015-04-01 伊沃菲姆股份有限公司 用于增强避孕杀微生物剂有效性的组合物和方法
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
MX2016008023A (es) 2013-12-19 2017-01-13 Evofem Inc Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.
AU2015201042A1 (en) 2014-02-28 2015-09-17 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic Method

Similar Documents

Publication Publication Date Title
WO2012079092A3 (en) Testosterone undecanoate compositions
JP2017514850A5 (enExample)
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
JP2016534153A5 (enExample)
RU2013125021A (ru) Местные композиции для сохранения или восстановления целостности слизистых оболочек
NZ612686A (en) Sublingual films
JP2014505733A5 (enExample)
MX2016000727A (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante.
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
RU2016129069A (ru) Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
NZ595663A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
RU2013134269A (ru) Полимерные системы
PH12015501312B1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
WO2013022243A3 (ko) 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
CN104337756A (zh) 一种壳聚糖妇科凝胶及其制备方法
JP2014510156A5 (enExample)
MX2013004117A (es) Formulacion farmaceutica para inhibidores de histona desacetilasa.
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
JP2015519398A5 (enExample)
JP2015519395A5 (enExample)
JP2015512948A5 (enExample)
RU2013147613A (ru) Местное дезинфицирующее средство, содержащее йод, обладающее низким содержанием поверхностно-активного вещества
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.